A detailed history of Raymond James & Associates transactions in Guardant Health, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 11,277 shares of GH stock, worth $282,939. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,277
Previous 17,142 34.21%
Holding current value
$282,939
Previous $353,000 7.93%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

SELL
$16.07 - $31.84 $94,250 - $186,741
-5,865 Reduced 34.21%
11,277 $325,000
Q1 2024

Apr 22, 2024

SELL
$17.13 - $26.91 $1.62 Million - $2.55 Million
-94,604 Reduced 84.66%
17,142 $353,000
Q4 2023

Jan 16, 2024

SELL
$21.58 - $29.5 $483,737 - $661,272
-22,416 Reduced 16.71%
111,746 $3.02 Million
Q3 2023

Oct 24, 2023

BUY
$25.8 - $39.97 $252,066 - $390,506
9,770 Added 7.85%
134,162 $3.98 Million
Q2 2023

Jul 25, 2023

SELL
$20.94 - $38.01 $83,676 - $151,887
-3,996 Reduced 3.11%
124,392 $4.45 Million
Q1 2023

Apr 14, 2023

SELL
$22.92 - $33.76 $70,501 - $103,845
-3,076 Reduced 2.34%
128,388 $3.01 Million
Q4 2022

Feb 08, 2023

SELL
$25.44 - $59.78 $505,950 - $1.19 Million
-19,888 Reduced 13.14%
131,464 $3.58 Million
Q3 2022

Oct 25, 2022

SELL
$43.66 - $61.0 $286,933 - $400,892
-6,572 Reduced 4.16%
151,352 $8.15 Million
Q2 2022

Aug 12, 2022

SELL
$28.82 - $77.35 $225,285 - $604,644
-7,817 Reduced 4.72%
157,924 $6.37 Million
Q1 2022

May 11, 2022

SELL
$48.25 - $100.49 $1.22 Million - $2.54 Million
-25,254 Reduced 13.22%
165,741 $11 Million
Q4 2021

Feb 08, 2022

SELL
$88.71 - $120.43 $778,164 - $1.06 Million
-8,772 Reduced 4.39%
190,995 $19.1 Million
Q3 2021

Nov 02, 2021

BUY
$98.77 - $132.17 $598,941 - $801,478
6,064 Added 3.13%
199,767 $25 Million
Q2 2021

Aug 11, 2021

SELL
$109.77 - $165.68 $348,739 - $526,365
-3,177 Reduced 1.61%
193,703 $24.1 Million
Q1 2021

May 14, 2021

SELL
$127.04 - $179.1 $1.6 Million - $2.25 Million
-12,573 Reduced 6.0%
196,880 $30.1 Million
Q4 2020

Feb 12, 2021

SELL
$99.96 - $135.93 $195,521 - $265,879
-1,956 Reduced 0.93%
209,453 $27 Million
Q3 2020

Nov 04, 2020

SELL
$80.32 - $111.8 $3.87 Million - $5.39 Million
-48,208 Reduced 18.57%
211,409 $23.6 Million
Q2 2020

Jul 28, 2020

BUY
$60.49 - $97.5 $236,999 - $382,005
3,918 Added 1.53%
259,617 $21.1 Million
Q1 2020

Apr 21, 2020

BUY
$59.04 - $88.81 $11.2 Million - $16.9 Million
189,906 Added 288.64%
255,699 $17.8 Million
Q4 2019

Feb 12, 2020

BUY
$59.49 - $82.78 $739,044 - $1.03 Million
12,423 Added 23.28%
65,793 $5.14 Million
Q3 2019

Nov 07, 2019

BUY
$62.59 - $110.3 $28,853 - $50,848
461 Added 0.87%
53,370 $3.41 Million
Q2 2019

Aug 06, 2019

BUY
$63.94 - $91.11 $3.05 Million - $4.35 Million
47,729 Added 921.41%
52,909 $4.57 Million
Q1 2019

May 06, 2019

BUY
$34.3 - $97.98 $177,673 - $507,536
5,180 New
5,180 $397,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $2.56B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.